These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465 [TBL] [Abstract][Full Text] [Related]
3. Ibrutinib and tracheal mucormycosis: A case report and systematic review of literature. Damaraju V; Agarwal R; Singh Sehgal I; Khadwal A; Bal A; Rudramurthy SM; Muthu V J Mycol Med; 2023 Aug; 33(3):101414. PubMed ID: 37523991 [TBL] [Abstract][Full Text] [Related]
4. The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy. Mascarella MA; Schweitzer L; Alreefi M; Silver J; Caglar D; Loo VG; Richardson K; Dufresne P; Lee TC; Sadeghi N J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):49. PubMed ID: 31619294 [TBL] [Abstract][Full Text] [Related]
5. Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria. Egger M; Gornicec M; Wölfler A; Lembeck AL; Tinchon C; Maderdonner M; Prattes J Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36029283 [TBL] [Abstract][Full Text] [Related]
6. Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. Stein MK; Karri S; Reynolds J; Owsley J; Wise A; Martin MG; Zare F World J Oncol; 2018 Apr; 9(2):62-65. PubMed ID: 29760835 [TBL] [Abstract][Full Text] [Related]
7. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study. Allouchery M; Brunet K; Tomowiak C; Singier A; Pambrun E; Pariente A; Bezin J; Pérault-Pochat MC; Salvo F Mycoses; 2024 Jan; 67(1):e13676. PubMed ID: 37984556 [TBL] [Abstract][Full Text] [Related]
9. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. Fehr M; Cathomas G; Graber A; Makert E; Gaus E; Boggian K Med Mycol Case Rep; 2020 Mar; 27():14-16. PubMed ID: 31890489 [TBL] [Abstract][Full Text] [Related]
10. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845 [TBL] [Abstract][Full Text] [Related]
11. Invasive Fungal Infection Complicating Treatment With Ibrutinib. Rajapakse P; Gupta M; Hall R Cureus; 2021 Jun; 13(6):e16009. PubMed ID: 34336499 [TBL] [Abstract][Full Text] [Related]
12. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Holowka T; Cheung H; Malinis M; Gan G; Deng Y; Perreault S; Isufi I; Azar MM J Infect Chemother; 2021 Dec; 27(12):1700-1705. PubMed ID: 34389223 [TBL] [Abstract][Full Text] [Related]
13. Risk of Invasive Fungal Infections in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors: A Case-Control Propensity Score-Matched Analysis. Agudelo Higuita NI; Chastain DB; Scott B; Sahra S; Vargas Barahona L; Henao Cordero J; Lee ALH; Tuells J; Henao-Martínez AF Open Forum Infect Dis; 2024 Jun; 11(6):ofae115. PubMed ID: 38887474 [TBL] [Abstract][Full Text] [Related]
14. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511 [TBL] [Abstract][Full Text] [Related]
15. [Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia]. Kumekawa H; Watanabe D; Tamura K; Mizuchi D Rinsho Ketsueki; 2022; 63(1):62-65. PubMed ID: 35135954 [TBL] [Abstract][Full Text] [Related]
17. Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor. Alkharabsheh O; Alsayed A; Morlote DM; Mehta A Curr Oncol; 2021 Feb; 28(1):837-841. PubMed ID: 33567487 [TBL] [Abstract][Full Text] [Related]
18. Rhino-orbital mucormycosis due to Apophysomyces ossiformis in a patient with diabetes mellitus: a case report. Martínez-Herrera E; Frías-De-León MG; Julián-Castrejón A; Cruz-Benítez L; Xicohtencatl-Cortes J; Hernández-Castro R BMC Infect Dis; 2020 Aug; 20(1):614. PubMed ID: 32811466 [TBL] [Abstract][Full Text] [Related]
19. A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. Eichenberger EM; Saullo J; Brander D; Wang SH; Perfect JR; Messina JA Med Mycol Case Rep; 2020 Mar; 27():17-21. PubMed ID: 31879587 [TBL] [Abstract][Full Text] [Related]
20. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. Titus-Rains KS; Brown JN; Hammond JM J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]